Article Data

  • Views 810
  • Dowloads 180

Case Reports

Open Access

Successful management of metastatic ovarian carcinosarcoma with olaparib plus bevacizumab: a case report

  • Takuya Yokoe1,*,
  • Masato Kita1
  • Gen-ichiro Sumi1
  • Hiroshi Shiraga1
  • Hidetaka Okada1

1Department of Obstetrics and Gynecology, Kansai Medical University, 573-1191 Hirakata, Osaka, Japan

DOI: 10.22514/ejgo.2022.002 Vol.43,Issue 3,June 2022 pp.147-151

Submitted: 12 December 2021 Accepted: 18 January 2022

Published: 15 June 2022

*Corresponding Author(s): Takuya Yokoe E-mail: yokoetk@hirakata.kmu.ac.jp

Abstract

Background: Ovarian carcinosarcoma (OCS) is a rare, highly aggressive, and treatment-resistant tumor. Some important advances in chemotherapy have been reported, including an anti-vascular endothelial growth factor antibody, bevacizumab (Bev)-containing regimen, and a poly-ADP ribose polymerase (PARP) inhibitor, olaparib. Olaparib is specifically a treatment option for OCSs with breast cancer gene (BRCA) mutations, and the clinical study on the combination of olaparib and Bev was reported for homologous recombination deficient epithelial ovarian cancer. However, there are no reports on treating advanced OCS with BRCA mutations by olaparib plus Bev effectively. In this study, to the best of our knowledge, we report the first case of successful management of multiple liver and para-aortic metastases of OCS with a BRCA mutation using olaparib plus Bev. Case: A 75-year-old woman presented to the hospital with complaints of abdominal distension. A staging laparotomy and histological analysis revealed a primary OCS. She received platinum doublet regimens as adjuvant chemotherapy. As myChoice® CDx test of the surgical specimen revealed a BRCA2 mutation, the combination regimen of olaparib (400 mg daily) plus Bev (15 mg/kg every three weeks) was chosen as the maintenance therapy. After four months of this chemotherapy, a computed tomography scan revealed significant shrinkage of both the liver metastases and para-aortic lymph nodes. Progression-free survival has been noted for over 14 months. Conclusions: The combination therapy of olaparib plus Bev could be a potential therapeutic option for advanced OCS.


Keywords

Ovarian carcinosarcoma; PARP inhibitor; Olaparib; Bevacizumab


Cite and Share

Takuya Yokoe,Masato Kita,Gen-ichiro Sumi,Hiroshi Shiraga,Hidetaka Okada. Successful management of metastatic ovarian carcinosarcoma with olaparib plus bevacizumab: a case report. European Journal of Gynaecological Oncology. 2022. 43(3);147-151.

References

[1] Muller M, Dupre P, Lucas B, Simon H, Malhaire J, Guillemet C, et al.[Carcinosarcoma of the ovary]. Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction. 2007; 36: 399–402.

[2] Brown E, Stewart M, Rye T, Al-Nafussi A, Williams ARW, Bradburn M, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer. 2004; 100: 2148–2153.

[3] Petru E, Kolovetsiou V, Idris T. Prolonged response to trabectedin in a patient with ovarian carcinosarcoma refractory to adjuvant platinum-taxane. Journal. Solid Tumors. 2013; 3: 9–11.

[4] Ray-Coquard IL, Leary A, Bigot F, Montane L, Fabbro M, Hardy-Bessard A, et al. ROCSAN trial (GINECO-EN203b/ENGOT-EN8): a multi-centric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum based chemotherapy. Journal of Clinical Oncology. 2021; 39: TPS5604–TPS5604.

[5] Koyanagi T, To Y, Ando M, et al. Primary peritoneal carcinosarcoma arising from the Douglas pouch: A case report. Molecular and clinical oncology. 2018; 9: 485–488.

[6] Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Clinical Cancer Research. 2014; 20: 764–775.

[7] Ni J, Zhou R, Cheng X, Xu X, Guo W, Chen X. Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series. Journal of Ovarian Research. 2020; 13: 29.

[8] Nagamata S, Nakasuji Y, Yamanaka K, Azumi M, Washio K, Shimizu M, et al. A Case of Significant Response to Olaparib in a Patient with Primary Peritoneal Carcinosarcoma Diagnosed by Laparoscopic Surgery. Case Reports in Obstetrics and Gynecology. 2020; 2020: 9106390.

[9] Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus Bevacizumab as first-Line Maintenance in Ovarian Cancer. New England Journal of Medicine. 2019; 381: 2416–2428.

[10] Makris GM, Siristatidis C, Battista MJ, Chrelias C. Ovarian carci-nosarcoma: a case report, diagnosis, treatment and literature review. Hippokratia. 2015; 19: 256–259.

[11] Olsen AB, Pargman S, Gillespie T. Solitary splenic metastasis from ovarian carcinosarcoma: a case report. Journal of Medical Case Reports. 2011; 5: 56.

[12] Asano M, Hasegawa K, Tsukada K, Tada S, Mizoguchi Y, Imaeda Y, et al. [A case and literature review of ovarian carcinosarcoma with long-term survival after repeated recurrences]. Gan to Kagaku Ryoho. Cancer & Chemotherapy. 2014; 41: 1031–1036.

[13] Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. Journal of Clinical Oncology. 2019; 37: 2317–2328.

[14] Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology. 2020; 38: 1222–1245.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top